All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Johnson & Johnson, Kura Oncology, Roche, Syndax and Thermo Fisher, and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
ASCO 2019 | How should hypomethylating agents be used in combination therapy?
Bookmark this article
Aref Al-Kali from the Mayo Clinic, Rochester, US, speaks with the AML Global Portal (AGP) during ASCO 2019 about how to optimize the use of hypomethylating agents in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Aref Al-Kali raises many questions within the topic, including whether azacitidine and decitabine should be used as single agents, or in combination with newer agents such as venetoclax. One particular topic that was of interest to the ASCO audience during Aref Al-Kali's talk during ASCO, was how to use fewer drugs, such as low dose azacitidine or decitabine, in patients with low-risk MDS.
How should hypomethylating agents be used in combination therapy?
More about...
Your opinion matters
29 votes - 44 days left ...
Related articles
Newsletter
Subscribe to get the best content related to AML delivered to your inbox